Pacific Point Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Pacific Point Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$565K	Sell	9,802 -15	-0.2%	-$861	0.26%	87
2026 Q1	$595K	Buy	9,817 +15	+0.2%	+$874	0.31%	83
2025 Q4	$529K	Hold	9,802	–	–	0.28%	92
2025 Q3	$442K	Hold	9,802	–	–	0.26%	89
2025 Q2	$454K	Hold	9,802	–	–	0.25%	86
2025 Q1	$598K	Hold	9,802	–	–	0.33%	63
2024 Q4	$579K	Buy	+9,802	New	+$548K	0.35%	66

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Pacific Point Advisors's BMY Position: Q2 2026 in Review

Pacific Point Advisors reduced its Bristol-Myers Squibb (BMY) stake by 0.15% in Q2 2026, selling an estimated $861 and leaving 9,802 shares worth $565K. The position accounts for 0.26% of the portfolio, ranked #87.

Pacific Point Advisors first reported a position in BMY in Q4 2024 and has held it in 7 quarters since. The position peaked at $598K in Q1 2025. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Pacific Point Advisors held 9,802 shares of Bristol-Myers Squibb worth $565K as of Q2 2026.
Pacific Point Advisors sold 15 Bristol-Myers Squibb shares in Q2 2026, an estimated $861.
Bristol-Myers Squibb made up 0.26% of Pacific Point Advisors's portfolio in Q2 2026, its #87 holding.
Pacific Point Advisors first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 7 quarters since.
Pacific Point Advisors's Bristol-Myers Squibb position peaked at $598K in Q1 2025.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Pacific Point Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.